EUVIMEDEUVIMED entdecken
Open Access · CC BY-SA 4.0

Description of Neonatal Age, Maternal Antithyroid Drug Use During Pregnancy, and Thyroid Stimulating Hormone Levels in the Congenital Hypothyroidism Screening Program

Wahyu Amanda Subari, Dwi Yulia, Rahmatini, Husni, Hudila Rifa Karmia, Gestina Aliska

INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY · 13.03.2026 · 32 (2) · 175-181

DOI: 10.24293/ijcpml.v32i2.2547 ↗

Kurz gefasst

Fachartikel in der Zeitschrift INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY, online erschienen am 13.03.2026. Verfasst von Wahyu Amanda Subari und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Congenital hypothyroidism is a hormonal disorder that can inhibit the cognitive and physical development of neonates. The government requires an early screening program for congenital hypothyroidism by measuring thyroid-stimulating hormone levels. Age at sampling and history of maternal use of antithyroid drugs during pregnancy may affect the test results. This study aims to provide an overview of neonatal age, history of antithyroid drug use during pregnancy, and thyroid-stimulating hormone levels in congenital hypothyroidism screening programs. A descriptive and quantitative design with secondary data from congenital hypothyroid screening papers was analyzed univariately. It also used the population from the total sampling technique, so the study sample was 1,003 neonates. Most neonates who underwent congenital hypothyroid screening sampling had normal thyroid-stimulating hormone levels, a distribution of sampling age that was by national guidelines (2-14 days), and divided per day and no history of maternal antithyroid drug use during pregnancy, the mean thyroid-stimulating hormone level in neonates screened for congenital hypothyroidism was 2.68±2.25 mU/L, 2.44±1.95 mU/L in those aged 2–14 days, and 2.68±2.25 mU/L in neonates born to mothers exposed to antithyroid drugs. These findings support the government's program in conducting comprehensive and timely early detection of congenital hypothyroidism.

Zitieren

APA

Subari, W. A., Yulia, D., Rahmatini, Husni, Karmia, H. R., & Aliska, G. (2026). Description of Neonatal Age, Maternal Antithyroid Drug Use During Pregnancy, and Thyroid Stimulating Hormone Levels in the Congenital Hypothyroidism Screening Program. INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY, 32(2), 175-181. https://doi.org/10.24293/ijcpml.v32i2.2547

Vancouver

Subari WA, Yulia D, Rahmatini, Husni, Karmia HR, Aliska G. Description of Neonatal Age, Maternal Antithyroid Drug Use During Pregnancy, and Thyroid Stimulating Hormone Levels in the Congenital Hypothyroidism Screening Program. INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY. 2026;32(2):175-181. doi:10.24293/ijcpml.v32i2.2547

BibTeX
@article{Subari2026,
  author = {Subari, Wahyu Amanda and Yulia, Dwi and Rahmatini and Husni and Karmia, Hudila Rifa and Aliska, Gestina},
  title = {Description of Neonatal Age, Maternal Antithyroid Drug Use During Pregnancy, and Thyroid Stimulating Hormone Levels in the Congenital Hypothyroidism Screening Program},
  journal = {INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY},
  year = {2026},
  volume = {32},
  number = {2},
  pages = {175--181},
  doi = {10.24293/ijcpml.v32i2.2547}
}
Kostenlos starten →